A preclinical study found that PD-L1 expression was upregulated in tumor cells after everolimus treatment in renal cell carcinoma tumor-bearing mice, and the combination of everolimus with anti-PD-L1 antibody significantly reduced tumor burden compared with the everolimus alone, increasing tumor infiltrating lymphocytes (TILs) and the ratio of cytotoxic CD8+ T cells to TILs [30]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.